1 l of 2093 patients without COVID-19 symptoms
were included in 14 participating centers; 1224 were scr
2 uninvolved free light chains (dFLC) >50 mg/L
were included in 15 centers between September of 2016 an
3 vement per month during the last time period
was included in a landmark-model to estimate adjusted ha
4 the output of the DNN, called the DNN score,
was included in a regression analysis alongside age, gen
5 0 Spanish adults (aged 20-30 y; 78.1% women)
were included in a 6-d cross-sectional study.
6 0 x 1 mm) from the remaining 71 BCS patients
were included in a blinded reader study, which resulted
7 Of 385 screened articles, 6
were included in a broad characterization and in the met
8 serum at admission, April 10 to June 30 2020
were included in a cohort.
9 e neurodegeneration, and 17 healthy controls
were included in a data-driven scaled subprofile model (
10 Seven studies
were included in a meta-analysis examining findings in m
11 United States were treated with axi-cel and
were included in a modified intent-to-treat (mITT) analy
12 circumference at birth, 5 mo, 12 mo, and 5 y
were included in a path model to estimate their total, i
13 with intracranial bleeding due to an AVM who
were included in a prospective database in the period co
14 h to prevent slit lamp evaluation of the PC,
were included in a simple sequence without randomization
15 A total of 2,579 had complete data and
were included in adjusted regression analyses.
16 2 severe asthmatic African American children
were included in an epigenome-wide association study.
17 s who received at least 1 dose of study drug
were included in analyses.
18 Two-hundred fifty-five children
were included in analysis after exclusion for underlying
19 s of clusters were created, and 107 of those
were included in animations that may be used to explore
20 in this silent system (Ala as the effector)
were included in changes previously identified for allos
21 3 adult patient cohorts with and without IBD
were included in data analyses.
22 t least one mRS score taken after day 5, and
were included in efficacy analyses.
23 tion models, but it is unclear if these will
be included in final legislation.
24 ces screened, 47 studies with 6,583 patients
were included in final analyses.
25 other factors required for protein synthesis
are included in full detail, several biological phenomen
26 th selective breeding and are recommended to
be included in future breeding goals.
27 lay of the PQ/cycle-length dependency should
be included in future non-invasive studies of atrial dep
28 mized, and note that single-gene CNVs should
be included in gene-focused studies using other classes
29 our RCTs, for a total of 6,158 participants,
were included in meta-analyses across the primary and se
30 Eligible studies
were included in meta-analyses.
31 mic artery [OA] vs. nonocclusive; P < 0.001)
were included in multivariate analysis, and occlusive ca
32 Therefore, data pertaining to 388 patients
is included in our analysis.
33 motherapy after surgery with curative intent
were included in our double-blind phase III multicenter
34 Five RCTs totaling 792 patients
were included in our meta-analysis after application of
35 048 citations that were screened, 24 studies
were included in our review.
36 A total of 62 subjects
were included in our study (n=38 patients with reverse t
37 All MOG antibody-positive cases
were included in our study, which assessed syndromes, tr
38 lving 1704 patients and 12 intervention arms
were included in our study.
39 ations between January 2006 and January 2019
were included in our study.
40 of 118 patients were randomly assigned; 117
were included in outcome analyses.
41 GW296115 is a compound that
was included in PKIS based on its promising selectivity
42 Each analyte class
was included in predictive modeling, and area under the
43 n, as very few Hispanic/Latino patients have
been included in previous studies.
44 risons was applied, and significant variants
were included in regression models adjusting for potenti
45 received at least one dose of treatment, and
were included in safety analyses.
46 sent at high densities, this effect needs to
be included in supernova nucleosynthesis models.
47 ging findings of the disorder, some of which
are included in the diagnostic criteria proposed in 2013
48 he main features of the small molecules that
are included in the EML, spanning from their origin, to
49 PET/CT is of value in early CRPC and should
be included in the CRPC entry criteria of the European A
50 Evaluation of FDNIH should
be included in the diagnostic workup of NSAIDH.
51 WD should
be included in the differential diagnosis of scleral nod
52 nonin and suggests that actinonin should not
be included in the highly valuable collection of 'irresi
53 tics of this novel virus, suggesting that it
be included in the novel Epsilonnudivirus genus (Nudivir
54 Anti-thymocyte globulin should
be included in the preparative regimens of patients with
55 Thirteen of the 29 studies could
be included in the quantitative analysis.
56 the probability of local spread, which must
be included in the structured report.
57 Of these, 32 were eligible to
be included in the study.
58 Homo rhodesiensis, but recently it has often
been included in the taxon Homo heidelbergensis(2-4).
59 ts who underwent SWI without these sequences
being included in the protocol.
60 ication may determine whether an observation
is included in the analysis.
61 Even though the species
is included in the IUCN Red List as Endangered, genetic
62 Fifty-five eyes
were included in the 2q4 group, and 58 eyes were include
63 were included in the 2q4 group, and 58 eyes
were included in the 2q8 group.
64 Of these, 124 (89%)
were included in the 6-month analysis, 92 (66%) in the 1
65 In all, 24 covariates per SNP/gene pair
were included in the AdaPT analysis using flexible gradi
66 , with a median age of 48 years; 421 and 649
were included in the adherence and VS analyses, respecti
67 burnout, depressive symptoms, and well being
were included in the American Society of Nephrology annu
68 Twenty-nine studies
were included in the analyses (20 studies were of good q
69 Among 294 randomized participants, 292 (99%)
were included in the analyses (mean [SD] age, 10.3 [1.2]
70 hether administered alone or as care bundles
were included in the analyses.
71 group and 423 in the transvenous ICD group)
were included in the analyses.
72 Fifty-two patients
were included in the analyses.
73 Two hundred seventy-eight patients
were included in the analysis (ranibizumab 0.5 mg, n = 1
74 ne group and 2677 women in the control group
were included in the analysis cohort for years 0-4, and
75 omen from the new unvaccinated control group
were included in the analysis cohort for years 7-11.
76 695 participants
were included in the analysis for efficacy, of whom 348
77 eclined or had withdrawn consent, 2463 (95%)
were included in the analysis of the primary outcome (me
78 A total 3,196 PHIVA
were included in the analysis with a median follow-up pe
79 Ultimately, 1,429 participants
were included in the analysis with an average age of 59
80 Of the 164 patients that
were included in the analysis, 57 patients received lipo
81 raviroc group) who received more than 1 dose
were included in the analysis.
82 orded gestational age of less than 37 weeks,
were included in the analysis.
83 and 241 nonoffspring donor liver transplants
were included in the analysis.
84 All eligible and treated patients
were included in the analysis.
85 secretor studies with data from 38 countries
were included in the analysis.
86 Survey and mortality follow-up through 2015
were included in the analysis.
87 mean age, 42.1 +/- 13.9 years; range, 18-65)
were included in the analysis.
88 9 EK procedures (n = 71,040 unique patients)
were included in the analysis.
89 A total of 418 patients
were included in the analysis.
90 eatment program during April 2015-March 2018
were included in the analysis.
91 e EK procedures (N = 71,040 unique patients)
were included in the analysis.
92 imary percutaneous coronary intervention and
were included in the analysis.
93 n and 9 men, for a total of 20 participants,
were included in the analysis.
94 l (n = 735 in both randomization groups) and
were included in the analysis.
95 ear pretreatment follow-up and yearly review
were included in the analysis.
96 tients with mild primary biliary cholangitis
were included in the analysis.
97 All consecutive patients with symptoms
were included in the analysis.
98 Seventy-one case patients and 300 controls
were included in the analysis.
99 (61.3%) and 4520 Latinx (38.7%) participants
were included in the analysis.
100 A total of 93 eyes of 77 patients
were included in the analysis.
101 rface antibody (anti-HBs) and anti-HBc tests
were included in the analysis.
102 84 patients (age: 34.23 (10.8), 80% female)
were included in the analysis.
103 A total of 2404 HEU and 3 605 864 HUU
were included in the analysis.
104 us disease 2019 patients admitted to the ICU
were included in the analysis.
105 four hundred sixty-five survey participants
were included in the analysis; 1932 had self-reported gl
106 ean serum urate level, 8.2 mg per deciliter)
were included in the assessment of the primary outcome.
107 ients with solid tumours or multiple myeloma
were included in the basket dose-expansion cohort (12 no
108 1) and serum CRP (beta = - 0.226, P = 0.019)
were included in the best model (R(2 ) = 0.12, F(3,152)
109 Two hundred and four patients
were included in the BSX group and 179 in the ATG group
110 ILO [73% female, mean (SD) age 53(16) years]
were included in the case note review.
111 Three hundred forty-six cases
were included in the case-series analysis.
112 ctic hemoclipping for delayed PPB prevention
were included in the clipping group, and those without p
113 mes; 18 RCTs for a total of 933 participants
were included in the component network meta-analysis.
114 A total of 11,966 patients
were included in the current study, of whom 3513 (29.36%
115 1, 1980 and Dec 31, 2015, 2 223 927 children
were included in the Danish Life Course cohort.
116 imary RRD in 2015 from 5 large retina groups
were included in the database.
117 to the study: 29 patients with solid tumours
were included in the dose-escalation cohort and 29 patie
118 Forty patients
were included in the e-HRT group (mean age 62.1 +/- 12.0
119 complete or two incomplete treatment cycles
were included in the efficacy population.
120 portant" by >= 50% of respondents in round 3
were included in the final "basket".
121 %) of which met the eligibility criteria and
were included in the final analysis (n=953 patients).
122 We identified 973 studies; of these, 82
were included in the final analysis, comprising 66,159 p
123 ents and 950 control participants from Spain
were included in the final analysis.
124 (50 clinical and 9 population-based genetic)
were included in the final analysis.
125 ollow up; therefore, a total of 666 patients
were included in the final cohort.
126 tical" and less than 15% "not important" and
were included in the final PICU core outcome set: four G
127 in 394 publications, of which 109 documents
were included in the final review.
128 hundred forty-six patients from 14 hospitals
were included in the final study cohort with an overall
129 Fifty-four women dropped out; 398
were included in the full analysis.
130 Ten patients
were included in the group with ITBA (n = 10 of 35; 28.6
131 ITBA (n = 10 of 35; 28.6%), and 25 patients
were included in the group without ITBA.
132 68 patients
were included in the HLH group and 34 each in the DC and
133 2, 2019, 293 patients were screened and 196
were included in the intention-to-treat population (97 i
134 articipants (7548 in the UK, 4088 in Brazil)
were included in the interim primary efficacy analysis.
135 the alert threshold; 15,487 hospitalizations
were included in the intervention cohort, and 28,462 hos
136 < 25 kg/m(2) and normal waist circumference
were included in the interventional analysis.
137 creened, 199 with SAB met study criteria and
were included in the investigation.
138 on criteria were identified and 132 patients
were included in the matched dataset (tocilizumab = 66;
139 104 modifiable factors and 11 interventions
were included in the meta-analyses.
140 ded in the systematic review and 119 studies
were included in the meta-analyses.
141 Fourteen studies
were included in the meta-analysis of obesity (BMI > 30
142 Nine factors
were included in the meta-analysis, stratified by HR and
143 ia for the systematic review, and 21 studies
were included in the meta-analysis.
144 A total of 39 articles
were included in the meta-analysis.
145 16 articles
were included in the meta-analysis.
146 Only observational studies
were included in the meta-analysis.
147 Of these, 119 studies
were included in the meta-analysis.
148 28 studies
were included in the meta-analysis.
149 ur (14.6%) showed inflammation on biopsy and
were included in the microscopic ileitis group.
150 e x environment or physiology x environment)
were included in the model compared to models with only
151 10 patients underwent randomization, and 700
were included in the modified intention-to-treat analysi
152 200 mg group, and 95 [86%] in 400 mg group)
were included in the modified intention-to-treat mainten
153 00 mg group, and 111 [100%] in 400 mg group)
were included in the modified intention-to-treat populat
154 and those without prophylactic hemoclipping
were included in the non-clipping group.
155 19 studies
were included in the overall pooled prevalence for each
156 atients with cataract surgery preceding AION
were included in the pcsAION cohort defined in 2 ways: A
157 pt 7, 2016, and Aug 18, 2017; 19 021 (94.6%)
were included in the per protocol analysis, and 20 071 (
158 108 participants
were included in the per-protocol analysis (56 in the to
159 fficacy analyses; the remaining 151 patients
were included in the per-protocol efficacy analyses.
160 ass index, 32.7 [5.7]; and 74.2% women), 600
were included in the per-protocol population used for th
161 A total of 595 and 422 patients
were included in the pre-intervention and intervention p
162 tients) and 909 (nurses) choice observations
were included in the preference models.
163 entry criteria for both natriuretic peptides
were included in the present analysis.
164 of 5 +/- 4.3 years (range: 1 to 16.8 years)
were included in the present article.
165 with moderate or severe HIE treated with TH
were included in the present study.
166 men with newly diagnosed prostate carcinoma
were included in the present study.
167 ndividuals without diabetes and hypertension
were included in the present study.
168 Of these, 408 (93%) participants
were included in the primary analysis (203 participants
169 Patients with available data
were included in the primary analysis and all assigned p
170 total of 7,991 patients from the test campus
were included in the primary analysis, and 4,264 were in
171 and 385 participants from the control group
were included in the primary analysis.
172 ed at least one dose of study medication and
were included in the primary analysis.
173 .9 [2.1] ng/mL), 443 eligible patients (93%)
were included in the primary analysis.
174 34.2%]), 296 (98.3%) completed the trial and
were included in the primary analysis.
175 All enrolled patients
were included in the primary and safety analyses.
176 Women
were included in the primary comparison regardless of co
177 -study (200 raltegravir, 194 efavirenz); 307
were included in the primary efficacy analysis (153 ralt
178 Thirty-five patients were enrolled, and 29
were included in the primary efficacy analysis as prespe
179 tive impairment [3 trials]) on follow-up and
were included in the primary meta-analysis, 8 reported c
180 n age, 68 years; 181 [55%] women), 320 (97%)
were included in the primary outcome analysis.
181 included in the primary analysis, and 4,264
were included in the propensity-score matched secondary
182 Twenty-seven
were included in the RCT and 27 in the OLT.
183 l group, respectively, and 1135 participants
were included in the reference cohort.
184 ancers reported until the next annual screen
were included in the reference standard for sensitivity
185 welve studies met the inclusion criteria and
were included in the review.
186 All patients who received treatment
were included in the safety analyses.
187 ed one dose of vosoritide or placebo (n=121)
were included in the safety analyses.
188 regimen with mosquito feeding at day 42, but
were included in the safety analyses.
189 All mothers and their infants
were included in the safety analysis, and 250 mothers (1
190 o received at least one dose of cabozantinib
were included in the safety analysis, and all participan
191 All patients who were given selinexor
were included in the safety analysis.
192 e enrolled and received both study drugs and
were included in the safety analysis.
193 e primary analysis and all assigned patients
were included in the safety analysis.
194 eceived at least one vaccine dose or placebo
were included in the safety analysis; immunogenicity was
195 eceived at least one dose of study treatment
were included in the safety population.
196 A total of 600 patients
were included in the study (average age, 61 years; range
197 ments and Main Results: Twenty-nine patients
were included in the study (median [25th-75th percentile
198 A total of 1,394 patients
were included in the study cohort (n = 700 in the pre-be
199 A total of 31,921 (61,833 eyes)
were included in the study for LASIK and 5,016 (9,467 ey
200 68 patients with COVID-19
were included in the study from April 13 to April 24, 20
201 ecystitis that underwent CT at our institute
were included in the study so as to have 1 : 1 control.
202 A total of 459 study participants
were included in the study with a response rate of 95.21
203 A total of 111 patients with DM II
were included in the study, 36 with DM without DR, 53 wi
204 adult patients who underwent cardiac surgery
were included in the study, and 347 (7.2%) were assisted
205 A total of 200 eyes
were included in the study, and HP was seen in 64 eyes (
206 Thirty eyes of 30 patients
were included in the study.
207 trols (mean age at death 91 years, one male)
were included in the study.
208 examinations with osseous PSMA-ligand uptake
were included in the study.
209 with interval resolution or decrease in size
were included in the study.
210 antitative polymerase chain reaction (qPCR),
were included in the study.
211 A total 73 subjects
were included in the study.
212 Finally, these 100 patients
were included in the study.
213 eye syndrome at ours or another institution
were included in the study.
214 [interquartile range] age 59 yr [48-67 yr])
were included in the study.
215 Thirty age- and sex-matched healthy subjects
were included in the study.
216 secutive PCa patients who underwent PSMA-PET
were included in the study.
217 Twenty patients
were included in the study.
218 scans of 45 patients (30 males, 15 females)
were included in the study.
219 A total of 997 eyes from 677 patients
were included in the study.
220 49 documented consecutive COVID-19 subjects
were included in the study.
221 ation, -2.31 dB) and 65 control participants
were included in the study.
222 bjects with FTD and 84 healthy subjects (HS)
were included in the study.
223 ufficient samples for diagnostic testing and
were included in the study.
224 A total of 72 infants
were included in the study.
225 02 participants from the EPIC-Norfolk cohort
were included in the study.
226 Fifty-two patients
were included in the study.
227 orts depicting cystic or tumour-like lesions
were included in the study.
228 Seventy-nine individuals
were included in the study; fifty cases and 28 controls
229 In total, 2007 and 2040 patients
were included in the surgery group and the control group
230 Eighteen studies
were included in the systematic evaluation and 11 in the
231 1 474 participants from 23 African countries
were included in the systematic review and 119 studies w
232 Fifty studies
were included in the systematic review and 19 in the met
233 Data from six articles
were included in the systematic review and meta-analysis
234 irst dose of assigned vaccine or placebo and
were included in the total vaccinated population.
235 012 to January 2016, a total of 280 patients
were included in the trial (laparoscopic surgery: n = 13
236 A total of 180 patients
were included in the trial (n = 80 observational and n =
237 rough November 2019, a total of 748 patients
were included in the trial after randomization - 375 wer
238 ramipril group and 52 in the control group)
were included in the trial.
239 cts of geometrical and mechanical properties
are included in this model and studied in detail.
240 Of 3166 papers found, 24
are included in this Review.
241 ls related to treatment of established CIPN,
are included in this update.
242 Different types of carboxylic acids have
been included in this review: monocarboxylic acids (like
243 All litigation involving glaucoma
was included in this analysis and was compared with liti
244 P; $9655 per person); 85.2% of that spending
was included in this study.
245 008 to 2016 while living within 15 km of LAX
were included in this analysis (N = 174,186; including 1
246 tine clearance <=30 mL/min) or liver disease
were included in this analysis (n=17 423).
247 A total of 220 eyes of 147 patients
were included in this analysis (US-Cat: n = 74 patients;
248 In total, 7555 patients
were included in this analysis, 3973 (53%) male and 3582
249 >=30 y old); 163 participants with SCFA data
were included in this analysis.
250 592 patients in each group
were included in this analysis.
251 153 eyes
were included in this analysis.
252 Eight parameters
were included in this analysis: proximal isovelocity sur
253 1 participants with SAF readings at baseline
were included in this analysis: The mean (+/- SD) age wa
254 Stroke Register (SLSR) between 2001 and 2018
were included in this cohort study.
255 ised; 34, segmental; and 32, focal cervical)
were included in this comprehensive analysis.
256 all, 24 articles (total participants = 3328)
were included in this comprehensive analysis.
257 Twenty-four eyes of 24 subjects with DME
were included in this institutional review board-approve
258 e Development of ALLergy [MeDALL] consortium
were included in this meta-analysis of the following stu
259 Methods: Sixteen patients
were included in this multicenter study.
260 sophageal carcinoma surgery in 2011 to 2018,
were included in this nationwide cohort study.
261 d age-matched and community-matched controls
were included in this post-hoc analysis if their mid-upp
262 Twenty patients with CMO secondary to CRVO
were included in this prospective cohort study.
263 Ninety-six patients with diabetes mellitus
were included in this prospective study and divided into
264 hospitals within the Northwell Health system
were included in this prospective, observational study.
265 valuated from January 2014 and December 2017
were included in this retrospective analysis of transped
266 tic patients treated with first-line Nab-Gem
were included in this retrospective analysis.
267 Fourteen patients receiving (225)Ac-PSMA-I&T
were included in this retrospective analysis.
268 eline and at 6 wk after treatment initiation
were included in this retrospective analysis.
269 coma clinic presenting between 2015 and 2019
were included in this retrospective case series.
270 hin a 6-month interval between 2008 and 2018
were included in this retrospective cohort study.
271 hospital between March 2008 and January 2019
were included in this retrospective cohort study.
272 ued from January 1, 2010 to October 1, 2017,
were included in this retrospective study.
273 Thirty COVID-19-positive patients
were included in this retrospective study.
274 Eighty-one articles
were included in this review, of which 12 were randomize
275 from the search and from manual searches, 71
were included in this review.
276 Twenty-two articles
were included in this review.
277 on]; age range, 27-70 years) with 37 lesions
were included in this study and underwent scanning using
278 medication and scheduled for trabeculectomy
were included in this study at a tertiary eye care cente
279 mmercial flakes from different raw materials
were included in this study, both gluten (barley, rye, s
280 A total of 102 eyes of 63 patients
were included in this study.
281 A total of 249 patients
were included in this study.
282 Forty-seven eyes from 24 patients
were included in this study.
283 A total of 305 patients
were included in this study.
284 thousand three hundred seventy-six patients
were included in this study.
285 ound or Endoscopy) episode of diverticulitis
were included in this study.
286 A total of 72 pure L-LLS
were included in this study.
287 ubjects and 73 eyes from 73 uveitis subjects
were included in this study.
288 e variants, in 23 genes across 164 patients,
were included in this study.
289 ticipants of the Health Workers Cohort Study
were included in this study.
290 ssified as clustered microcysts on US images
were included in this study.
291 Both male and female mice
were included in this study.
292 recent tuberculin skin test (TST) conversion
were included in this study.
293 Forty-five eyes from 45 patients
were included in this study.
294 treated with single-tooth maxillary implants
were included in this study.
295 A total of 1 511 602 patients
were included in this study: 24 892 OAG patients and 1 4
296 A total of 103 eyes
were included in this study: 51 uncomplicated primary an
297 e hundred twenty-nine eyes from 329 patients
were included in this study: 90 nondiabetic patients, 17
298 dex, portfolio, pulse, and Paleolithic diets
were included in this umbrella review.
299 have developed COVID-19 after their stroke,
were included in two logistic regression analyses examin
300 egative cases without chemotherapy treatment
were included in which all four tests were available (n